Celgene (NASDAQ: CELG) in a report of research report published on Friday, January 5. The firm currently has a purchase rating on the shares of the biopharmaceutical company.
Several other stock research analysts have also issued reports on CELG. Purchase rating and issued a price target of $ 150.00 on Celgene shares in a report on Tuesday, September 12. Bank of America reiterated a purchase rating of Celgene shares in a report on Wednesday, September 13. Royal Bank of Canada Celgene's coverage began in a report on Thursday, September 14. Top pick rating and a price target of $ 176.00 in the stock, Jefferies Group reissued a purchase rating and issued A target price of $ 160.00 on Celgene shares was set in a research note on Friday, September 15. Finally, Robert W. Baird reissued a purchase rating and issued a $ 16 2.00 target price on Celgene shares in a research note on Thursday, September 21. Two stock research analysts have rated the stock with a sale rating, thirteen have issued a withholding grade, eighteen have assigned a purchase rating and one has issued a strong purchase rating to the stock. Currently, the company has an average Buy score and an average target price of $ 129.98.
Celgene (NASDAQ: CELG) quoted at $ 0.93 during Friday's trading hours, reaching $ 102.65. The share had a trading volume of 8,098,686 shares, compared to its average volume of 6,610,000. Celgene has a minimum of 52 weeks of $ 94.55 and a maximum of 52 weeks of $ 147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a fast ratio of 3.52. The company has a market capitalization of $ 81,560.00, a PE ratio of 24.21, a PEG ratio of 0.65 and a beta of 1.77.
Celgene (NASDAQ: CELG) last published its quarterly earnings data on Thursday, October 26. The biopharmaceutical company reported earnings per share of $ 1.91 (EPS) for the quarter, surpassing the Thomson Reuters consensus estimate of $ 1.87 for $ 0.04. Celgene had a return on capital of 63.80% and a net margin of 27.36%. The company had revenues of $ 3.29 billion for the quarter, compared to analyst expectations of $ 3.42 billion. During the same period of the previous year, the company registered $ 1.58 EPS. Celgene's revenues grew 10.2% compared to the same quarter of the previous year. Stock research analysts expect Celgene to post 6.7 earnings per share for the current year.
Recently, several hedge funds have added or reduced their holdings in CELG. PNC Financial Services Group Inc. increased its holdings in Celgene by 13.2% in the first quarter. PNC Financial Services Group Inc. now owns 787,046 shares of the biopharmaceutical company valued at $ 97,934,000 after buying 91,679 additional shares during the last quarter. Legal & General Group Plc increased its holdings in Celgene by 4.3% in the first quarter. Legal & General Group Plc now holds 3,587,623 shares of the biopharmaceutical company, valued at $ 446,406,000 after buying 147,263 additional shares during the last quarter. State Street Corp increased its holdings in Celgene by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company valued at $ 4,040,668,000 after buying 723,844 additional shares during the last quarter. Wedgewood Partners Inc. acquired a new stake in Celgene in the first quarter valued at approximately $ 23,890,000. Finally, Cypress Capital Group increased its holdings in Celgene by 4.8% in the first quarter. Cypress Capital Group now owns 35,292 shares of the biopharmaceutical company's stock valued at $ 4,392,000 after buying 1,602 additional shares during the last quarter. 79.85% of the shares are currently owned by hedge funds and other institutional investors.
WARNING: This article was first published by StockNewsTimes and is owned by StockNewsTimes. If you are accessing this article on another website, it was copied and forwarded illegally in violation of the US. UU And of international legislation on trademarks and copyrights. The correct version of this article can be seen at https://stocknewstimes.com/2018/01/20/celgene-celg-given-a-128-00-price-target-at-mizuho-2.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is dedicated to the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuroinflammation.
Receive news and ratings from Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and ratings from analysts for Celgene and companies related to the FREE daily bulletin of MarketBeat.com.